MCID: HMN014
MIFTS: 53

Human Immunodeficiency Virus Infectious Disease

Categories: Immune diseases, Infectious diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Human Immunodeficiency Virus Infectious Disease

MalaCards integrated aliases for Human Immunodeficiency Virus Infectious Disease:

Name: Human Immunodeficiency Virus Infectious Disease 11 14
Hiv Infections 14

Classifications:



External Ids:

Disease Ontology 11 DOID:526
ICD9CM 34 042-042.99
MeSH 43 D015658
NCIt 49 C3108
SNOMED-CT 68 86406008
ICD10 31 B20
UMLS 71 C0019693

Summaries for Human Immunodeficiency Virus Infectious Disease

Disease Ontology: 11 A viral infectious disease that results in destruction of immune system, leading to life-threatening opportunistic infections and cancers, has material basis in Human immunodeficiency virus 1 or has material basis in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. The virus infects helper T cells (CD4+ T cells) which are directly or indirectly destroyed, macrophages, and dendritic cells. The infection has symptom diarrhea, has symptom fatigue, has symptom fever, has symptom vaginal yeast infection, has symptom headache, has symptom mouth sores, has symptom muscle aches, has symptom sore throat, and has symptom swollen lymph glands.

MalaCards based summary: Human Immunodeficiency Virus Infectious Disease, also known as hiv infections, is related to acquired immunodeficiency syndrome and human immunodeficiency virus type 1. An important gene associated with Human Immunodeficiency Virus Infectious Disease is CCR5 (C-C Motif Chemokine Receptor 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lercanidipine and Candesartan cilexetil have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and liver, and related phenotypes are neoplasm and endocrine/exocrine gland

Related Diseases for Human Immunodeficiency Virus Infectious Disease

Diseases related to Human Immunodeficiency Virus Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 588)
# Related Disease Score Top Affiliating Genes
1 acquired immunodeficiency syndrome 32.6 TNF ITIH4 IL2 IL10 IFNG IFNA1
2 human immunodeficiency virus type 1 31.5 ITIH4 IL7 IL2 IL10 IFNG ERVW-1
3 syphilis 31.4 TNF CD4 CD209 CCR5 B2M
4 chlamydia 31.1 TNF IL10 IFNG CCR5
5 candidiasis 31.0 TNF IL2 IL10 IFNG
6 pneumocystosis 31.0 TNF IL2 IL10 IFNG CD4
7 immune deficiency disease 31.0 TNF ITIH4 IL7R IL7 IL2 IL10
8 hepatitis c 30.9 IL10 IFNG IFNA1 CD209
9 viral infectious disease 30.9 TNF ITIH4 IL7R IL7 IL2 IL10
10 hepatitis a 30.9 TNF IL10 IFNG IFNA1 CD4 CCR5
11 toxoplasmosis 30.8 TNF IL10 IFNG CCR5 CCL3
12 herpes zoster 30.8 IL2 IL10 IFNG IFNA1 CD4 CCR5
13 oral hairy leukoplakia 30.8 ITIH4 IL10 CD4
14 trichomoniasis 30.7 TNF IL10 CD4 CCR5 CCL5 CCL4
15 diarrhea 30.7 TNF IL2 IL10 IFNG IFNA1
16 peripheral nervous system disease 30.7 TNF IL2 IL10 IFNG IFNA1 CXCR4
17 secondary syphilis 30.7 TNF CD4 CCR5
18 anogenital venereal wart 30.6 TNF IL2 IFNA1 CD4
19 anterior uveitis 30.6 TNF IL2 IL10 IFNG CD4
20 mycobacterium tuberculosis 1 30.6 TNF IL7 IL10 IFNG CXCR4 CD4
21 bacterial pneumonia 30.6 TNF IL10 IFNG CD4 CCL3
22 bacterial vaginosis 30.6 TNF IL10 CD4 CCR5 CCL5 CCL4
23 uveitis 30.6 TNF IL2 IL10 IFNG CCR5 CCL4
24 otitis media 30.6 TNF IL2 IL10 IFNG CCL5
25 skin disease 30.6 TNF IL7R IL7 IL2 IL10 IFNG
26 cytomegalovirus retinitis 30.6 TNF IL10 IFNG CXCL12 CD9 CD4
27 lymphoma, non-hodgkin, familial 30.5 IL7 IL2 CXCR4 CXCL12 CD4 CD38
28 deficiency anemia 30.5 TNF IL2 IL10 IFNA1 CD4 CD38
29 acute retinal necrosis syndrome 30.4 TNF IL10 CD4
30 dermatitis 30.4 TNF IL2 IL10 IFNG
31 choroiditis 30.4 TNF IL10 IFNG CD4
32 keratoconjunctivitis 30.4 TNF IL2 IFNG CCR5
33 plague 30.4 TNF IL2 IL10 CD4 CCR5
34 pneumonia 30.4 TNF IL10 IFNG CCL5 CCL3
35 aphthous stomatitis 30.4 TNF IL2 IL10 IFNG CD4
36 posterior uveitis 30.4 TNF IL2 CD4
37 blepharitis 30.4 TNF IL2 CD4
38 septic arthritis 30.4 TNF IL10 CD4
39 human cytomegalovirus infection 30.4 TNF IL10 CD4
40 parasitic helminthiasis infectious disease 30.4 TNF IL2 IL10 IFNG CD4
41 extrinsic allergic alveolitis 30.4 TNF CD4 CCL5 CCL3 B2M
42 lymphoid interstitial pneumonia 30.4 TNF IL2 IFNG CD4 B2M
43 meningoencephalitis 30.4 TNF IL10 CD4 CCL5 B2M
44 anus disease 30.4 TNF IL2 CD4
45 toxic shock syndrome 30.4 TNF IL2 IL10 IFNG
46 conjunctivitis 30.4 TNF IL7 IL2 IL10 IFNG
47 gingivitis 30.4 TNF IL2 IL10 IFNG CCL5
48 periodontitis 30.4 TNF IL2 IL10 IFNG
49 aseptic meningitis 30.4 TNF IL10 IFNA1 CD4 CCL3
50 endocarditis 30.4 TNF IL10 IFNG CCL4

Graphical network of the top 20 diseases related to Human Immunodeficiency Virus Infectious Disease:



Diseases related to Human Immunodeficiency Virus Infectious Disease

Symptoms & Phenotypes for Human Immunodeficiency Virus Infectious Disease

GenomeRNAi Phenotypes related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 B2M CCL3 CCL4 CCL5 CCR5 CD209
2 no effect GR00402-S-2 10.18 B2M CCL3 CCL4 CCL5 CCR5 CD209

MGI Mouse Phenotypes related to Human Immunodeficiency Virus Infectious Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.16 B2M CCR5 CD9 CXCR4 IFNG IL10
2 endocrine/exocrine gland MP:0005379 10.15 B2M CD38 CD4 CD9 CXCR4 IFNG
3 cellular MP:0005384 10.13 B2M CCL3 CCR5 CD209 CD38 CD4
4 immune system MP:0005387 10.09 B2M CCL3 CCL5 CCR5 CD209 CD38
5 digestive/alimentary MP:0005381 10.02 B2M CCL3 CCR5 CD209 CD4 CXCR4
6 liver/biliary system MP:0005370 10.01 B2M CCR5 CXCL12 IFNG IL10 IL2
7 no phenotypic analysis MP:0003012 9.98 CD4 CXCL12 IFNG IL10 IL2 IL7
8 respiratory system MP:0005388 9.56 CCR5 CD9 CXCR4 IFNA1 IFNG IL10
9 hematopoietic system MP:0005397 9.55 B2M CCL3 CCL5 CCR5 CD209 CD38

Drugs & Therapeutics for Human Immunodeficiency Virus Infectious Disease

Drugs for Human Immunodeficiency Virus Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 808)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
2
Candesartan cilexetil Approved Phase 4 145040-37-5
3
Zalcitabine Approved, Investigational Phase 4 7481-89-2 24066
4
Didanosine Approved Phase 4 69655-05-6 50599
5
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7, 53152-21-9 644073 40400
6
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
7
Sulfamethoxazole Approved Phase 4 723-46-6 5329
8
Lopinavir Approved Phase 4 192725-17-0 92727
9
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
10
Megestrol acetate Approved, Investigational, Vet_approved Phase 4 595-33-5 11683
11
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
12
Elvitegravir Approved Phase 4 697761-98-1 23083982 5277135
13
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
14
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
15
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
16
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
17
Indinavir Approved Phase 4 150378-17-9 5362440
18
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
19
Fosamprenavir Approved Phase 4 226700-79-4 131536
20
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
21
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
22
Pravastatin Approved Phase 4 81093-37-0 54687
23
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
24
Zoledronic acid Approved Phase 4 118072-93-8 68740
25
Lactitol Approved, Investigational Phase 4 585-86-4 157355
26
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
27
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
28
Atovaquone Approved Phase 4 95233-18-4 74989
29
Proguanil Approved Phase 4 500-92-5 4923 6178111
30
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
31
Famotidine Approved Phase 4 76824-35-6 3325 5702160
32
Artenimol Approved, Experimental, Investigational Phase 4 71939-50-9 540327
33
Piperaquine Approved, Experimental, Investigational Phase 4 4085-31-8
34
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0, 19085-09-7 4993
35
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
36
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
37
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
38
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
39
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
40
Cytarabine Approved, Investigational Phase 4 147-94-4 6253
41
Doxepin Approved, Investigational Phase 4 1668-19-5 667468 667477
42
Temazepam Approved, Investigational Phase 4 846-50-4 5391
43
Amprenavir Approved, Investigational Phase 4 161814-49-9 65016
44
Aminosalicylic acid Approved Phase 4 65-49-6 4649
45
Ketoconazole Approved, Investigational Phase 4 65277-42-1, 142128-57-2 47576 3823 638701
46
Foscarnet Approved Phase 4 63585-09-1, 4428-95-9 3415
47
Clarithromycin Approved Phase 4 81103-11-9 84029
48
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
49
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
50
Magnesium sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9

Interventional clinical trials:

(show top 50) (show all 5231)
# Name Status NCT ID Phase Drugs
1 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
2 A Pilot Study of Highly Active Antiretroviral Therapy Using Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Antiretroviral Naive HIV-Infected Subjects Unknown status NCT00740064 Phase 4 Raltegravir and Abacavir/Lamivudine
3 Efecto de la Isoprinosina en Pacientes Con infección Por VIH y Carga Viral Entre > 50 y < 200 Copias/mL de la Unidad de atención de PVV Del Hospital Enrique Garcés en Quito, Ecuador Durante el año 2019. Unknown status NCT03883334 Phase 4 Metisoprinol
4 Multicenter, Open, Pilot Clinical Trial Aimed to Compare the Efficacy of RAL1200 QD vs DRV-cb 800-150 QD Both in Combination With TAF/FTC in Patients With HIV Infection and CD4 Count Under 200 Cells/microL Unknown status NCT03842488 Phase 4 Experimental: RAL QD;Active comparator: DRV/cb
5 Open Label Phase 4, 48 Week Pilot Study of the Antiviral Efficacy and Tolerability of the Combination of Isentress™ and ReyatazTM When Substituted for Current Antiviral Regimen in Patients With Viral Suppression But Who Are Experiencing Adverse Events Related to Their Current Antiviral Regimen. Unknown status NCT00751153 Phase 4 Raltegravir and Atazanavir
6 An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
7 A Phase IV, Multicenter, Open and Randomized Study to Assess the Impact of the Change From Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With Type 1 HIV Infection. InSTINCT Study Unknown status NCT04076423 Phase 4 Dual Therapy;Triple therapy
8 Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study Unknown status NCT03732625 Phase 4 Raltegravir
9 Impact of HIV-1 and Aging on Mucosal Vaccine Responses Unknown status NCT03729778 Phase 4
10 Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population (ProPositive Study) Unknown status NCT03682939 Phase 4
11 Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-naive HIV-infected Subjects Unknown status NCT00759070 Phase 4 Tenofovir + emtricitabine + efavirenz;Tenofovir + emtricitabine + lopinavir/ritonavir
12 Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Receiving Protease Inhibitors: a Randomized, Prospective, Controlled Pilot Study. Unknown status NCT00843661 Phase 4 ezetimibe;fenofibrate;pravastatin
13 A Randomized Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
14 Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring Unknown status NCT00836212 Phase 4 Reducing dose of Lopinavir;Reducing dose of efavirenz
15 Efficacy of Pentoxyfylline Addition to a Treatment Scheme Based on Interferon Alpha and Ribavirin on Hepatitis C Virus Coinfected HIV Patients, Considering Interleukin 28B Polymorphism rs12979860 Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
16 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
17 Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
18 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4 Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
19 A Phase IV, Open-label, Multicenter and Single-arm on the Immunogenicity of Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017 Unknown status NCT03626467 Phase 4
20 Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
21 A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who Are Antiretroviral Therapy Naive Unknown status NCT00005017 Phase 4 Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
22 A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients Unknown status NCT00005000 Phase 4 Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
23 Evaluating Inflammatory and Immunological Changes of HIV-positive Patients Switching to DTG Dual Regimen Compared to Those Switching to a Triple Drugs Regimen (B/F/TAF) Unknown status NCT04054089 Phase 4 Bictegravir 50 MG / Emtricitabine 200 MG / Tenofovir Alafenamide 25 MG [Biktarvy];dolutegravir 50 mg / lamivudine 300 mg
24 Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
25 A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
26 Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine Unknown status NCT00564057 Phase 4 candesartan;lercanidipine
27 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
28 SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model Unknown status NCT00241930 Phase 4
29 Pilot, Open-label, Randomized, Single-center Study to Asses a Simplification Strategy From Protease Inhibitors to Raltegravir: Once Daily Isentress (ODIS) Unknown status NCT00941083 Phase 4 Raltegravir (Use RAL as a simplification strategy)
30 Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy in Brazil: a "Real Life" Study Unknown status NCT01049685 Phase 4 First-line Antiretroviral Therapy
31 Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI) Treated With Multitarget Antiviral Therapy (MT-ART) Unknown status NCT04225325 Phase 4
32 A Prospective, Single Arm, Open-label 96 Week Observational Trial of the Tolerability, Adherence and Efficacy of a Dolutegravir/Abacavir/Lamivudine Single Tablet Regimen in HIV-1 Antibody Positive People Living With HIV With a History of Injection Drug Use Switching From Existing ART or Starting Treatment After Discontinuation of ART Unknown status NCT02659761 Phase 4 dolutegravir/abacavir/lamivudine
33 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
34 Effectiveness of Booster Vaccination With 1 or 2 Doses of Hepatitis A Vaccine Among HIV-infected Patients During an Ongoing Outbreak in Taiwan Unknown status NCT03855176 Phase 4 Vaqta Injectable Product
35 Empiric Treatment for Suspected Acute HIV Infection in the Emergency Department Unknown status NCT03711253 Phase 4 Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg
36 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
37 Prospective Pilot Study of the Efficacy, Safety and Tolerability of Bictegravir-Based HIV ART Same-Day Treatment Evaluations (B-HASTE) Unknown status NCT04249037 Phase 4 bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF);Standard initiation of antiretroviral therapy (ART)
38 Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed Unknown status NCT04132674 Phase 4 Bictegravir/emtricitabine/tenofovir alafenamide
39 Study of the Immunogenicity and Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected Adults Unknown status NCT03041051 Phase 4
40 Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
41 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
42 Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial). Unknown status NCT02337322 Phase 4 Dolutegravir;Darunavir/r
43 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
44 Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B Unknown status NCT03120494 Phase 4 Emtricitabine and Tenofovir
45 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
46 Pilot Study of the Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection Unknown status NCT01343225 Phase 4 atripla;darunavir ritonavir raltegravir
47 Phase IV, Randomized, Open Label, Crossover, Intervention Trial to Investigate the Effect of the Switch of Lopinavir/Ritonavir to Raltegravir on Endothelial Function, Chronic Inflammation, Immune Activation and HIV Replication <50 Copies/ml Unknown status NCT01453933 Phase 4 raltegravir
48 Entecavir Intensification for Persistent Hepatitis B Virus (HBV) Viremia in HIV-HBV Infection Completed NCT00662545 Phase 4 Entecavir with continued standard of care antiretroviral therapy;continued standard of care with tenofovir in addition to emtricitabine or lamivudine
49 Efficacy and Safety of Switching From AZT to Tenofovir Completed NCT00647244 Phase 4 Tenofovir disoproxil fumarate;Abacavir
50 Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation Completed NCT03314064 Phase 4 Dolutegravir 50 mg

Search NIH Clinical Center for Human Immunodeficiency Virus Infectious Disease

Genetic Tests for Human Immunodeficiency Virus Infectious Disease

Anatomical Context for Human Immunodeficiency Virus Infectious Disease

Organs/tissues related to Human Immunodeficiency Virus Infectious Disease:

MalaCards : T Cells, Breast, Liver, Lymph Node, Bone Marrow, Endothelial, Bone

Publications for Human Immunodeficiency Virus Infectious Disease

Articles related to Human Immunodeficiency Virus Infectious Disease:

(show top 50) (show all 7362)
# Title Authors PMID Year
1
Rapid detection of HIV-1 p24 antigen using magnetic immuno-chromatography (MICT). 53 62
19482361 2009
2
Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. 53 62
19535523 2009
3
Expression and production of human interleukin-7 in insect cells using baculovirus expression vector system (BEVS). 53 62
18546077 2008
4
Emerging antiviral drugs. 53 62
18764719 2008
5
A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. 53 62
18096673 2008
6
A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection. 53 62
16439866 2006
7
Mycobacterium tuberculosis upregulates coreceptors CCR5 and CXCR4 while HIV modulates CD14 favoring concurrent infection. 53 62
16438645 2006
8
RNAi-directed inhibition of DC-SIGN by dendritic cells: prospects for HIV-1 therapy. 53 62
16353935 2005
9
Association of drug abuse with inhibition of HIV-1 immune responses: studies with long-term of HIV-1 non-progressors. 53 62
14741421 2004
10
Polymorphisms of CCR5 gene in a southern Chinese population and their effects on disease progression in HIV infections. 53 62
12461425 2002
11
Oral mucosal immunity and HIV infection: current status. 53 62
12164661 2002
12
Autoantibodies to TNFalpha in HIV-1 infection: prospects for anti-cytokine vaccine therapy. 53 62
11237281 2001
13
Correlation of virus load and soluble L-selectin, a marker of immune activation, in pediatric HIV-1 infection. 53 62
11101052 2000
14
Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4. 53 62
10195751 1999
15
[Early diagnosis of primary HIV infections: using a combined screening test (p24 antigen and anti-HIV antibodies)]. 53 62
10189669 1999
16
Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection. 53 62
10231014 1999
17
Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. 53 62
9612607 1998
18
New perspectives for the treatment of HIV infections. 53 62
9646721 1998
19
The role of biological response modifiers on apoptosis in HIV infections and AIDS. 53 62
17451286 1996
20
Solution conformation of an immunogenic peptide derived from the principal neutralizing determinant of the HIV-2 envelope glycoprotein gp125. 53 62
9079375 1996
21
Differential effects of human immunodeficiency virus type 1 envelope protein gp120 on interferon production by mononuclear cells from adults and neonates. 53 62
7583919 1995
22
Zinc and immune function. 53 62
7478075 1995
23
Immunologic marker paths for seroconversion: single determinations of immunoglobulin A and beta 2-microglobulin are not adequate to estimate time of HIV infection. Multicohort Analysis Project Workshop. Part II. 53 62
7946101 1994
24
[Interferon-gamma. Therapy of recurrent furunculosis in HIV infections]. 53 62
8104915 1993
25
Effectiveness of assays for antibodies to HIV and p24 antigen to detect very recent HIV infections in blood donors. The Retrovirus Study Group of the French Society of Blood Transfusion. 53 62
1492941 1992
26
Chemsex and incidence of sexually transmitted infections among Canadian pre-exposure prophylaxis (PrEP) users in the l'Actuel PrEP Cohort (2013-2020). 62
35039437 2022
27
Brief Report: Use of Pre-Exposure Prophylaxis to Prevent Rapid HIV Transmission Among People Who Inject Drugs in Rural Counties in the United States: A Modeling Study. 62
36150038 2022
28
HIV and adolescent girls and young women in sub-Saharan Africa: A call for expedited action to reduce new infections. 62
36147901 2022
29
Evaluating the time of HIV infection, diagnosis and treatment delays based on HIV notification data in Northwest China, 2008–19. 62
36170977 2022
30
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. 62
36356603 2022
31
Impact of COVID-19 on the Belgian HIV epidemic: slowdown of HIV transmission and testing and adaptation of care. 62
36463126 2022
32
Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya. 62
36111533 2022
33
Preexposure Prophylaxis for HIV Prevention in a Rural Southern Clinic. 62
36455891 2022
34
HIV Services and Outcomes During the COVID-19 Pandemic - United States, 2019-2021. 62
36454696 2022
35
Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention? 62
36468218 2022
36
Liver Transplantation in HIV-Infected Patient. 62
36474393 2022
37
Challenges with couples HIV counselling and testing among black MSM students: perspectives of university students in Durban, South Africa. 62
35912646 2022
38
Correlates of HIV Testing across the lifespan - adolescence through later adulthood - among sexual minority men in the US who are not on PrEP. 62
35916966 2022
39
Intersecting Communities and PrEP Uptake among US-based Latinx Sexual Minority Men. 62
34554441 2022
40
'Oh, I don't really want to bother with that:' gay and bisexual young men's perceptions of barriers to PrEP information and uptake. 62
34524938 2022
41
Combining the HYM (Healthy Young Men's) Cohort Study and the TRUTH (A Trans Youth of Color Study): Protocol for an Expanded Mixed Methods Study Renewal. 62
36326811 2022
42
Eligibility criteria vs. need for pre-exposure prophylaxis: a reappraisal among men who have sex with men in Amsterdam, the Netherlands. 62
36440637 2022
43
Validation of HIV Pre-Exposure Prophylaxis (PrEP) Medication Scales with Youth on PrEP: PrEP Confidence Scale and PrEP Difficulties Scale. 62
36306520 2022
44
PrEP use and stigma among a sample of older adults in Columbus, Ohio. 62
36424190 2022
45
Experiences of Mothers Living With HIV in a South African Prevention of Mother-to-Child Transmission of HIV Programme: A Qualitative Descriptive Study. 62
36355599 2022
46
CD20+ T cells: an emerging T cell subset in human pathology. 62
35951029 2022
47
Recent HIV Infection Among Men Who Have Sex with Men, Transgender Women, and Genderqueer Individuals with Newly Diagnosed HIV Infection in Zimbabwe: Results from a Respondent-Driven Sampling Survey. 62
35923140 2022
48
Transmission network and phylogenetic analysis reveal older male-centered transmission of CRF01_AE and CRF07_BC in Guangxi, China. 62
36369697 2022
49
Distribution of HIV Self-tests by Men Who have Sex with Men (MSM) to Social Network Associates. 62
36318431 2022
50
Tele-counseling based on motivational interviewing to change sexual behavior of women living with HIV: a randomized controlled clinical trial. 62
35467228 2022

Variations for Human Immunodeficiency Virus Infectious Disease

Expression for Human Immunodeficiency Virus Infectious Disease

Search GEO for disease gene expression data for Human Immunodeficiency Virus Infectious Disease.

Pathways for Human Immunodeficiency Virus Infectious Disease



Pathways directly related to Human Immunodeficiency Virus Infectious Disease:

(show all 49)
# Pathway Source
1 HIV Infection Reactome 66
2 HIV Life Cycle Reactome 66
3 Budding and maturation of HIV virion Reactome 66
4 Late Phase of HIV Life Cycle Reactome 66
5 Host Interactions of HIV factors Reactome 66
6 Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters Reactome 66
7 Nef mediated downregulation of MHC class I complex cell surface expression Reactome 66
8 Vif-mediated degradation of APOBEC3G Reactome 66
9 Vpu mediated degradation of CD4 Reactome 66
10 Formation of HIV elongation complex in the absence of HIV Tat Reactome 66
11 RNA Polymerase II HIV Promoter Escape Reactome 66
12 HIV Transcription Initiation Reactome 66
13 Transcription of the HIV genome Reactome 66
14 RNA Pol II CTD phosphorylation and interaction with CE during HIV infection Reactome 66
15 Formation of the HIV-1 Early Elongation Complex Reactome 66
16 HIV Transcription Elongation Reactome 66
17 Tat-mediated elongation of the HIV-1 transcript Reactome 66
18 Formation of HIV-1 elongation complex containing HIV-1 Tat Reactome 66
19 Interactions of Tat with host cellular proteins Reactome 66
20 Pausing and recovery of HIV elongation Reactome 66
21 Pausing and recovery of Tat-mediated HIV elongation Reactome 66
22 Tat-mediated HIV elongation arrest and recovery Reactome 66
23 HIV elongation arrest and recovery Reactome 66
24 Rev-mediated nuclear export of HIV RNA Reactome 66
25 Vpr-mediated nuclear import of PICs Reactome 66
26 Nuclear import of Rev protein Reactome 66
27 Interactions of Vpr with host cellular proteins Reactome 66
28 Interactions of Rev with host cellular proteins Reactome 66
29 APOBEC3G mediated resistance to HIV-1 infection Reactome 66
30 Autointegration results in viral DNA circles Reactome 66
31 Integration of viral DNA into host genomic DNA Reactome 66
32 Early Phase of HIV Life Cycle Reactome 66
33 Integration of provirus Reactome 66
34 2-LTR circle formation Reactome 66
35 Nef Mediated CD8 Down-regulation Reactome 66
36 Nef mediated downregulation of CD28 cell surface expression Reactome 66
37 Nef Mediated CD4 Down-regulation Reactome 66
38 Binding and entry of HIV virion Reactome 66
39 Membrane binding and targetting of GAG proteins Reactome 66
40 Assembly Of The HIV Virion Reactome 66
41 Synthesis And Processing Of GAG, GAGPOL Polyproteins Reactome 66
42 Uncoating of the HIV Virion Reactome 66
43 Synthesis and processing of ENV and VPU Reactome 66
44 Minus-strand DNA synthesis Reactome 66
45 Nef and signal transduction Reactome 66
46 Plus-strand DNA synthesis Reactome 66
47 Reverse Transcription of HIV RNA Reactome 66
48 Abortive elongation of HIV-1 transcript in the absence of Tat Reactome 66
49 Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization Reactome 66

Pathways related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 TNF IL7R IL7 IL2 IL10 IFNG
2
Show member pathways
13.87 TNF IL7R IL7 IL2 IL10 CXCR4
3
Show member pathways
13.66 TNF IL7R IL7 IL2 IL10 IFNG
4
Show member pathways
13.59 CCL3 CCL4 CCL5 CD4 CXCL12 CXCR4
5
Show member pathways
13.49 CCL3 CCL4 CCL5 CCR5 CD4 CXCL12
6
Show member pathways
13.34 CCL3 CCL4 CCL5 CCR5 CD4 CXCL12
7
Show member pathways
13.26 B2M CCL3 CCL4 CCL5 CCR5 CD4
8
Show member pathways
12.93 CCL3 CCL4 CCL5 CCR5 CD4 CXCL12
9
Show member pathways
12.91 TNF IL2 IFNA1 CD209 CCL5 CCL4
10
Show member pathways
12.73 TNF IL7R IL2 IL10 IFNG IFNA1
11
Show member pathways
12.68 TNF IFNG CXCR4 CD4 CCR5
12
Show member pathways
12.61 TNF IL2 IL10 IFNG CD4
13 12.47 TNF IL2 IL10 IFNG IFNA1 CXCR4
14
Show member pathways
12.23 TNF IL2 IL10 IFNG CD4
15
Show member pathways
12.17 CXCR4 CXCL12 CCR5 CCL5 CCL4 CCL3
16
Show member pathways
12.07 IL2 IFNG CD4 CCR5 CCL4 CCL3
17
Show member pathways
12.03 TNF IL2 IL10 IFNG CD4
18 11.98 CXCL12 IFNG IL10 IL2 TNF
19 11.95 IL10 CXCR4 CCR5 CCL3
20 11.91 IL2 IL10 IFNG CXCR4 CD4 CCR5
21 11.85 TNF IL2 IL10 IFNG CXCR4 CXCL12
22 11.76 TNF CXCR4 CXCL12
23 11.76 TNF CCL5 CCL4 CCL3
24 11.75 TNF IL10 CCL4 CCL3
25
Show member pathways
11.73 TNF IL2 IL10 IFNG
26 11.72 IL2 IFNG CD4
27 11.72 IL2 IL10 IFNG
28
Show member pathways
11.7 TNF IL2 IFNG
29 11.69 CCL3 CCL4 CCL5 IL10 TNF
30
Show member pathways
11.67 TNF IL2 IFNG
31 11.66 CCL3 CD4 IFNG IL10 IL2 IL7
32 11.63 TNF IL2 IL10 IFNG CD4
33 11.62 CXCR4 CXCL12 CD4
34 11.61 TNF IL10 CCR5 CCL5 CCL4 CCL3
35 11.6 IL2 IL10 IFNG CD4
36
Show member pathways
11.44 TNF IL2 IL10 IFNG CCL4 CCL3
37 11.43 TNF IL7R IL2 IL10 IFNG CD4
38 11.38 TNF IFNG CCL5 CCL4 CCL3
39 11.36 TNF IL7 IFNG
40 11.35 CCL5 CXCL12 CXCR4
41 11.34 TNF IL2 IL10 IFNG
42 11.34 TNF IL7R IL7 IL2 IL10 IFNG
43 11.3 TNF IFNA1 CCL3
44 11.28 IL2 IFNG CD4
45 11.26 IL2 IL10 IFNG
46 11.26 TNF IL7 IL2 IL10 IFNG CD4
47 11.1 TNF IL7 IL2 IL10 CXCL12 CCL5
48 11.01 IL2 IFNG CD4 CCR5 CCL4
49 10.71 IL2 IFNG
50 10.71 IL2 CCL3

GO Terms for Human Immunodeficiency Virus Infectious Disease

Cellular components related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.23 B2M CCL3 CCL4 CCL5 CD9 CXCL12
2 extracellular region GO:0005576 10.12 B2M CCL3 CCL4 CCL5 CD209 CD9
3 cell surface GO:0009986 10.03 TNF CXCR4 CD4 CD38 CD209 CCR5
4 external side of plasma membrane GO:0009897 9.58 TNF IL7R CXCR4 CXCL12 CD9 CD4

Biological processes related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 10.44 CCL3 CCL4 CCL5 CCR5 CXCR4 TNF
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.34 TNF CD4 CCL5 CCL4 CCL3
3 signal transduction GO:0007165 10.3 CCL3 CCL4 CCL5 CCR5 CD38 CD4
4 MAPK cascade GO:0000165 10.28 TNF CCR5 CCL5 CCL3
5 cell-cell signaling GO:0007267 10.27 CCL3 CCL4 CCL5 CCR5 IL2 IL7
6 positive regulation of inflammatory response GO:0050729 10.25 CCL3 IFNG IL2 TNF
7 viral entry into host cell GO:0046718 10.25 CXCR4 CD4 CD209 CCR5
8 cellular response to type II interferon GO:0071346 10.22 CCL3 CCL4 CCL5 TNF
9 regulation of insulin secretion GO:0050796 10.17 TNF IFNG CCL5
10 response to activity GO:0014823 10.17 TNF IL10 CXCR4
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.17 CCL5 IFNG IL2 TNF
12 positive regulation of B cell proliferation GO:0030890 10.16 IL7 IL2 CD38
13 monocyte chemotaxis GO:0002548 10.16 CCL5 CCL4 CCL3
14 positive regulation of chemokine production GO:0032722 10.16 TNF IL7 IFNG
15 calcium-mediated signaling GO:0019722 10.16 CCL3 CCR5 CD4 CXCR4 TNF
16 lipopolysaccharide-mediated signaling pathway GO:0031663 10.14 TNF CCL5 CCL3
17 humoral immune response GO:0006959 10.14 IFNA1 IFNG IL7 TNF
18 lymphocyte chemotaxis GO:0048247 10.13 CCL5 CCL4 CCL3
19 positive regulation of calcium ion transport GO:0051928 10.09 CCL5 CCL4 CCL3
20 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.08 TNF IL7R IL10 CCL5
21 T cell differentiation GO:0030217 10.07 CD4 IL2 IL7R
22 chemotaxis GO:0006935 10.07 CCL3 CCL4 CCL5 CCR5 CXCL12 CXCR4
23 defense response GO:0006952 10.06 TNF IFNA1 CXCL12 CCR5
24 positive regulation of calcium-mediated signaling GO:0050850 10.05 CD4 CCL4 CCL3
25 eosinophil chemotaxis GO:0048245 10.03 CCL5 CCL4 CCL3
26 cell chemotaxis GO:0060326 10.03 CXCR4 CXCL12 CCR5 CCL5 CCL3
27 response to virus GO:0009615 10.03 TNF IFNG CXCR4 CXCL12 CCL5 CCL4
28 dendritic cell chemotaxis GO:0002407 10.02 CXCR4 CCR5 CCL5
29 regulation of calcium ion transport GO:0051924 10.01 CXCR4 CXCL12 CD4
30 signaling GO:0023052 10 TNF CCR5 CCL3
31 detection of mechanical stimulus involved in sensory perception of pain GO:0050966 10 TNF CXCR4 CXCL12
32 negative regulation by host of viral transcription GO:0043922 9.99 CCL5 CCL4 CCL3
33 negative regulation of cytokine production involved in immune response GO:0002719 9.97 TNF IL10
34 telencephalon cell migration GO:0022029 9.97 CXCR4 CXCL12
35 positive regulation of plasma cell differentiation GO:1900100 9.94 IL2 IL10
36 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.93 TNF IFNG
37 positive regulation of nitrogen compound metabolic process GO:0051173 9.93 TNF IFNG
38 chronic inflammatory response to antigenic stimulus GO:0002439 9.9 IL10 TNF
39 positive regulation of vitamin D biosynthetic process GO:0060557 9.89 IFNG TNF
40 response to ultrasound GO:1990478 9.88 CXCL12 CXCR4
41 positive regulation of natural killer cell chemotaxis GO:2000503 9.88 CCL5 CCL4 CCL3
42 B cell proliferation GO:0042100 9.85 CD38 IFNA1 IL10 IL7 IL7R
43 chemokine-mediated signaling pathway GO:0070098 9.7 CXCR4 CXCL12 CCR5 CCL5 CCL4 CCL3
44 immune response GO:0006955 9.64 TNF IL7R IL7 IL2 IL10 IFNG

Molecular functions related to Human Immunodeficiency Virus Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.92 CXCR4 CD4 CD209 CCR5
2 coreceptor activity GO:0015026 9.88 CXCR4 CD4 CCR5
3 chemokine activity GO:0008009 9.86 CXCL12 CCL5 CCL4 CCL3
4 CCR chemokine receptor binding GO:0048020 9.85 CCL5 CCL4 CCL3
5 CCR5 chemokine receptor binding GO:0031730 9.63 CCL3 CCL4 CCL5
6 cytokine activity GO:0005125 9.55 TNF IL7 IL2 IL10 IFNG IFNA1
7 CCR1 chemokine receptor binding GO:0031726 9.43 CCL5 CCL4 CCL3

Sources for Human Immunodeficiency Virus Infectious Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....